Hims & Hers Health (NYSE:HIMS) Shares Gap Down Following Insider Selling

Hims & Hers Health, Inc. (NYSE:HIMS)’s stock price gapped down before the market opened on Thursday after an insider sold shares in the company. The stock had previously closed at $68.74, but opened at $65.08. Hims & Hers Health shares last traded at $63.33, with a volume of 9,502,094 shares trading hands.

Specifically, insider Soleil Boughton sold 4,152 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $60.69, for a total value of $251,984.88. Following the sale, the insider now directly owns 157,345 shares of the company’s stock, valued at approximately $9,549,268.05. This represents a 2.57 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link. Also, CEO Andrew Dudum sold 128,127 shares of the stock in a transaction that occurred on Tuesday, February 18th. The shares were sold at an average price of $58.27, for a total transaction of $7,465,960.29. Following the completion of the sale, the chief executive officer now directly owns 97,687 shares in the company, valued at approximately $5,692,221.49. This represents a 56.74 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In other Hims & Hers Health news, COO Melissa Baird sold 67,687 shares of the stock in a transaction that occurred on Wednesday, February 12th. The shares were sold at an average price of $44.71, for a total value of $3,026,285.77. Following the sale, the chief operating officer now directly owns 706,872 shares of the company’s stock, valued at approximately $31,604,247.12. This represents a 8.74 % decrease in their position. The sale was disclosed in a document filed with the SEC, which is available at this link.

Wall Street Analyst Weigh In

Several research analysts have recently issued reports on the stock. Deutsche Bank Aktiengesellschaft upped their target price on shares of Hims & Hers Health from $23.00 to $27.00 and gave the company a “hold” rating in a report on Wednesday, November 6th. Citigroup cut shares of Hims & Hers Health from a “neutral” rating to a “sell” rating and upped their target price for the company from $24.00 to $25.00 in a report on Friday, January 10th. Bank of America upped their target price on shares of Hims & Hers Health from $18.00 to $21.00 and gave the company an “underperform” rating in a report on Thursday. TD Cowen restated a “buy” rating and issued a $28.00 target price on shares of Hims & Hers Health in a report on Wednesday, November 20th. Finally, Piper Sandler upped their target price on shares of Hims & Hers Health from $21.00 to $24.00 and gave the company a “neutral” rating in a report on Monday, January 6th. Two equities research analysts have rated the stock with a sell rating, eight have given a hold rating and seven have assigned a buy rating to the company. Based on data from MarketBeat.com, the company has an average rating of “Hold” and a consensus target price of $28.53.

Hims & Hers Health Trading Down 26.1 %

The company has a market cap of $10.73 billion, a price-to-earnings ratio of 111.58 and a beta of 1.35. The company’s 50 day moving average price is $35.05 and its 200 day moving average price is $25.70.

Institutional Trading of Hims & Hers Health

Several hedge funds have recently made changes to their positions in HIMS. Crewe Advisors LLC acquired a new stake in shares of Hims & Hers Health in the 4th quarter worth $28,000. Raleigh Capital Management Inc. lifted its stake in shares of Hims & Hers Health by 1,100.0% in the 4th quarter. Raleigh Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after acquiring an additional 1,100 shares during the period. Blume Capital Management Inc. lifted its stake in shares of Hims & Hers Health by 100.0% in the 4th quarter. Blume Capital Management Inc. now owns 1,200 shares of the company’s stock worth $29,000 after acquiring an additional 600 shares during the period. Smartleaf Asset Management LLC lifted its stake in shares of Hims & Hers Health by 4,415.6% in the 4th quarter. Smartleaf Asset Management LLC now owns 1,445 shares of the company’s stock worth $36,000 after acquiring an additional 1,413 shares during the period. Finally, Summit Securities Group LLC purchased a new position in shares of Hims & Hers Health in the 4th quarter valued at about $38,000. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth consultation platform. It connects consumers to healthcare professionals, enabling them to access medical care for mental health, sexual health, dermatology and primary care. The company was founded in 2017 and is headquartered in San Francisco, CA.